PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Protein Expression and Genetic Variation of IL32 and Association with Colorectal Cancer in Swedish Patients.

Abstract Interleukin 32 (IL32) is an intracellular pluripotent cytokine produced by epithelial cells, monocytes, T-lymphocytes and natural killer cells and seems to be involved in the pathogenesis of cancer and inflammatory diseases. Our purpose was to assess the role of protein expression and genetic polymorphisms of IL32 in colorectal cancer (CRC) susceptibility.
PMID
Related Publications

Interleukin promoter polymorphisms and prognosis in colorectal cancer.

Gene polymorphism of matrix metalloproteinase-12 and -13 and association with colorectal cancer in Swedish patients.

KRAS and VEGF gene 3'-UTR single nucleotide polymorphisms predicted susceptibility in colorectal cancer.

CD93 gene polymorphism is associated with disseminated colorectal cancer.

Role of cytokine gene polymorphisms in gastric cancer risk in Chile.

Authors

Mayor MeshTerms

Genetic Predisposition to Disease

Keywords

IL32

SNP

colorectal cancer

protein expression

Journal Title anticancer research
Publication Year Start




PMID- 29277790
OWN - NLM
STAT- MEDLINE
DCOM- 20180104
LR  - 20180104
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Protein Expression and Genetic Variation of IL32 and Association with Colorectal 
      Cancer in Swedish Patients.
PG  - 321-328
AB  - BACKGROUND: Interleukin 32 (IL32) is an intracellular pluripotent cytokine
      produced by epithelial cells, monocytes, T-lymphocytes and natural killer cells
      and seems to be involved in the pathogenesis of cancer and inflammatory diseases.
      Our purpose was to assess the role of protein expression and genetic
      polymorphisms of IL32 in colorectal cancer (CRC) susceptibility. MATERIALS AND
      METHODS: To gain insight into clinical significance of IL32 in Swedish patients
      with CRC, using enzyme-linked immunosorbent assay, we determined whether IL32
      protein level is altered in CRC tissue (n=75) compared with paired normal tissue 
      and in plasma from patients with CRC (n=94) compared with controls (n=81). The
      expression of IL32 protein was confirmed by immunohistochemistry (n=73). We used 
      Luminex technology to investigate protein levels of the cytokines IL6, tumor
      necrosis factor-alpha (TNFalpha) and vascular endothelial growth factor (VEGF) to
      relate these to IL32 levels in CRC tissue. Three single nucleotide polymorphisms 
      (SNPs) (rs28372698, rs12934561, rs4786370) of the IL32 gene have been proposed as
      modifiers for different diseases. The present study evaluated the susceptibility 
      of patients possessing these SNPs to CRC. Using TaqMan SNP genotyping assays,
      these SNPs were screened in Swedish patients with CRC (n=465) and healthy
      controls (n=331). RESULTS: We found no significant differences in the genotypic
      frequencies between the patients and healthy controls and no relation to survival
      for any of the SNPs. However, the SNP rs12934561 was statisticalLY significant
      associated with older patients. IL32 protein was up-regulated in CRC tissue and
      related to IL6, TNFalpha, and VEGF, and seems to be modulated by SNP rs28372698. 
      The IL32 protein level in CRC tissue also reflects both disseminated disease and 
      location. CONCLUSION: Our results suggest that altered IL32 protein
      concentrations in CRC tissue and genotypic variants of IL32 are related to
      disseminated CRC.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Shamoun, Levar
AU  - Shamoun L
AD  - Division of Medical Diagnostics, Department of Laboratory Medicine, Jonkoping
      County, Jonkoping, Sweden.
FAU - Kolodziej, Blanka
AU  - Kolodziej B
AD  - Department of Pathology, Jonkoping County, Jonkoping, Sweden.
FAU - Andersson, Roland E
AU  - Andersson RE
AD  - Department of Surgery, Jonkoping County, Jonkoping, Sweden.
AD  - Department of Clinical and Experimental Medicine, Faculty of Medicine and Health 
      Sciences, Linkoping University, Linkoping, Sweden.
FAU - Dimberg, Jan
AU  - Dimberg J
AD  - Department of Natural Science and Biomedicine, School of Health and Welfare,
      Jonkoping University, Jonkoping, Sweden [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (IL32 protein, human)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - 0 (Interleukins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/metabolism
MH  - Colorectal Neoplasms/*genetics/pathology
MH  - Early Detection of Cancer/*methods
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Humans
MH  - Interleukin-6/metabolism
MH  - Interleukins/blood/*genetics/metabolism
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - Sweden
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Vascular Endothelial Growth Factor A/metabolism
OTO - NOTNLM
OT  - *IL32
OT  - *SNP
OT  - *colorectal cancer
OT  - *protein expression
EDAT- 2017/12/27 06:00
MHDA- 2018/01/05 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/16 00:00 [received]
PHST- 2017/10/31 00:00 [revised]
PHST- 2017/11/01 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
AID - 38/1/321 [pii]
AID - 10.21873/anticanres.12225 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):321-328. doi: 10.21873/anticanres.12225.